Therefore, our present results might complement previous meta-analyses by adding that selectivity of SGLT2 inhibitors is a significant predictor of stroke outcomes, in fact, combined SGLT1/2 inhibition might constitute a novel pharmacological approach to reduce adverse stroke outcomes in type 2 diabetic patients who are inherently at greater risk. Here, SLC5A2 is linked to stroke disorder.